150 related articles for article (PubMed ID: 11095972)
1. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.
Sakamoto J; Kimura H; Moriyama S; Odaka H; Momose Y; Sugiyama Y; Sawada H
Biochem Biophys Res Commun; 2000 Nov; 278(3):704-11. PubMed ID: 11095972
[TBL] [Abstract][Full Text] [Related]
2. An update on the mechanisms of action of the peroxisome proliferator-activated receptors (PPARs) and their roles in inflammation and cancer.
Gelman L; Fruchart JC; Auwerx J
Cell Mol Life Sci; 1999 Jun; 55(6-7):932-43. PubMed ID: 10412372
[TBL] [Abstract][Full Text] [Related]
3. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
[TBL] [Abstract][Full Text] [Related]
4. The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.
Bogacka I; Xie H; Bray GA; Smith SR
Diabetes Care; 2004 Jul; 27(7):1660-7. PubMed ID: 15220243
[TBL] [Abstract][Full Text] [Related]
5. Pioglitazone: mechanism of action.
Smith U
Int J Clin Pract Suppl; 2001 Sep; (121):13-8. PubMed ID: 11594239
[TBL] [Abstract][Full Text] [Related]
6. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).
Lehmann JM; Moore LB; Smith-Oliver TA; Wilkison WO; Willson TM; Kliewer SA
J Biol Chem; 1995 Jun; 270(22):12953-6. PubMed ID: 7768881
[TBL] [Abstract][Full Text] [Related]
7. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.
Turner RM; Kwok CS; Chen-Turner C; Maduakor CA; Singh S; Loke YK
Br J Clin Pharmacol; 2014 Aug; 78(2):258-73. PubMed ID: 24325197
[TBL] [Abstract][Full Text] [Related]
8. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.
Bosetti C; Rosato V; Buniato D; Zambon A; La Vecchia C; Corrao G
Oncologist; 2013; 18(2):148-56. PubMed ID: 23345544
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies.
Tseng CH; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2012; 30(4):368-402. PubMed ID: 23167631
[TBL] [Abstract][Full Text] [Related]
10. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis.
Colmers IN; Bowker SL; Majumdar SR; Johnson JA
CMAJ; 2012 Sep; 184(12):E675-83. PubMed ID: 22761478
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones.
Yki-Järvinen H
N Engl J Med; 2004 Sep; 351(11):1106-18. PubMed ID: 15356308
[No Abstract] [Full Text] [Related]
12. Current treatment of insulin resistance in type 2 diabetes mellitus.
Tan MH
Int J Clin Pract Suppl; 2000 Oct; (113):54-62. PubMed ID: 11965833
[TBL] [Abstract][Full Text] [Related]
13. Prospective de novo drug design with deep interactome learning.
Atz K; Cotos L; Isert C; Håkansson M; Focht D; Hilleke M; Nippa DF; Iff M; Ledergerber J; Schiebroek CCG; Romeo V; Hiss JA; Merk D; Schneider P; Kuhn B; Grether U; Schneider G
Nat Commun; 2024 Apr; 15(1):3408. PubMed ID: 38649351
[TBL] [Abstract][Full Text] [Related]
14. Fasting upregulates the monocarboxylate transporter MCT1 at the rat blood-brain barrier through PPAR δ activation.
Chasseigneaux S; Cochois-Guégan V; Lecorgne L; Lochus M; Nicolic S; Blugeon C; Jourdren L; Gomez-Zepeda D; Tenzer S; Sanquer S; Nivet-Antoine V; Menet MC; Laplanche JL; Declèves X; Cisternino S; Saubaméa B
Fluids Barriers CNS; 2024 Apr; 21(1):33. PubMed ID: 38589879
[TBL] [Abstract][Full Text] [Related]
15. Vimentin protein is a factor for decreasing breast cancer cell proliferation co-culture with human bone marrow-derived mesenchymal stem cells pre-treated with thiazolidinedione solutions.
Kwok LS; Yian SS; Ismael LQ; Bee YTG; Harn GL; Yin KB
Mol Biol Rep; 2024 Feb; 51(1):317. PubMed ID: 38381204
[TBL] [Abstract][Full Text] [Related]
16. Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases.
Martiniakova M; Biro R; Kovacova V; Babikova M; Zemanova N; Mondockova V; Omelka R
J Mol Med (Berl); 2024 Apr; 102(4):435-452. PubMed ID: 38363329
[TBL] [Abstract][Full Text] [Related]
17. Adolescent polycystic ovary syndrome without obesity: HOTAIR rs1443512 genotype relates to fat mass and to the redistribution of fat mass on low-dose pioglitazone.
de Zegher F; Díaz M; Ibáñez L
J Endocrinol Invest; 2024 Apr; 47(4):1037-1043. PubMed ID: 37805962
[TBL] [Abstract][Full Text] [Related]
18. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Burris TP; de Vera IMS; Cote I; Flaveny CA; Wanninayake US; Chatterjee A; Walker JK; Steinauer N; Zhang J; Coons LA; Korach KS; Cain DW; Hollenberg AN; Webb P; Forrest D; Jetten AM; Edwards DP; Grimm SL; Hartig S; Lange CA; Richer JK; Sartorius CA; Tetel M; Billon C; Elgendy B; Hegazy L; Griffett K; Peinetti N; Burnstein KL; Hughes TS; Sitaula S; Stayrook KR; Culver A; Murray MH; Finck BN; Cidlowski JA
Pharmacol Rev; 2023 Nov; 75(6):1233-1318. PubMed ID: 37586884
[TBL] [Abstract][Full Text] [Related]
19. Selective PPAR-Delta/PPAR-Gamma Activation Improves Cognition in a Model of Alzheimer's Disease.
Steinke I; Govindarajulu M; Pinky PD; Bloemer J; Yoo S; Ward T; Schaedig T; Young T; Wibowo FS; Suppiramaniam V; Amin RH
Cells; 2023 Apr; 12(8):. PubMed ID: 37190025
[No Abstract] [Full Text] [Related]
20. Screening for DAX1/EWS-FLI1 functional inhibitors identified dihydroorotate dehydrogenase as a therapeutic target for Ewing's sarcoma.
Watanabe M; Kosaka H; Sugawara M; Maemoto M; Ono Y; Uemori T; Shizu R; Yoshinari K
Cancer Med; 2023 Apr; 12(8):9802-9814. PubMed ID: 36825574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
